BP
LXRX icon

BBR Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

BBR Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-570,000
Closed -$263K – 257
2025
Q1 		$263K Buy
570,000
+100,000
+21% +$63.1K 0.02% 190
2024
Q4 		$347K Hold
470,000
– – 0.02% 183
2024
Q3 		$738K Buy
470,000
+200,000
+74% +$356K 0.06% 101
2024
Q2 		$454K Buy
270,000
+240,000
+800% +$431K 0.04% 118
2024
Q1 		$72K Buy
+30,000
New +$64.4K 0.01% 250

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBR Partners's LXRX Position: Q2 2025 in Review

BBR Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 570,000 shares — an estimated $263K sold.

BBR Partners first reported a position in LXRX in Q1 2024 and held it in 5 quarters. The position peaked at $738K in Q3 2024. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • BBR Partners reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • BBR Partners sold 570,000 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $263K.
  • BBR Partners first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • BBR Partners's Lexicon Pharmaceuticals position peaked at $738K in Q3 2024.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on BBR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.